New Triple-Threat treatment tested for tough skin cancer
NCT ID NCT06056895
Summary
This study is testing a combination of three immunotherapy drugs for patients with advanced Merkel cell carcinoma, a rare and aggressive skin cancer, that has spread and stopped responding to a common first-line treatment. The drugs are designed to work together to reactivate the patient's own immune system to attack the cancer. The goal is to see if this combination can stop or shrink tumors in patients who have few other options.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MERKEL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington, 98109, United States
Conditions
Explore the condition pages connected to this study.